(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 9.50%
0.79% $ 2.56
@ $20.32
Wydano: 8 vas. 2024 @ 16:30
Zwrot: -87.40%
Poprzedni sygnał: vas. 6 - 19:43
Poprzedni sygnał:
Zwrot: 0.27 %
Live Chart Being Loaded With Signals
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 167 963 |
Średni wolumen | 480 919 |
Kapitalizacja rynkowa | 76.21M |
EPS | $-0.650 ( 2023-11-09 ) |
Następna data zysków | ( $-0.610 ) 2024-05-09 |
Last Dividend | $0.656 ( 2018-01-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.930 |
ATR14 | $0.0120 (0.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Eckburg Paul | Buy | 30 000 | Common Stock |
2024-03-15 | Day Lucy | Buy | 55 000 | Stock Option (right to buy) |
2024-03-15 | Day Lucy | Buy | 27 500 | Common Stock |
2024-03-15 | Eizen Joshua M | Buy | 60 000 | Stock Option (right to buy) |
2024-03-15 | Eizen Joshua M | Buy | 30 000 | Common Stock |
INSIDER POWER |
---|
65.40 |
Last 100 transactions |
Buy: 3 449 514 | Sell: 642 134 |
Wolumen Korelacja
Anthem Inc. Corporate Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
SFL | 0.949 |
MIC | 0.937 |
X | 0.923 |
APO-PA | 0.921 |
FLSP | 0.92 |
UBS | 0.912 |
CEIX | 0.907 |
PSN | 0.903 |
CXW | 0.901 |
HRB | 0.898 |
10 Najbardziej negatywne korelacje | |
---|---|
HE | -0.92 |
ENIA | -0.915 |
AGTI | -0.909 |
RMD | -0.906 |
SFUN | -0.903 |
FNA | -0.899 |
NWE | -0.899 |
K | -0.898 |
HIPO | -0.89 |
NUV | -0.888 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Anthem Inc. Corporate Korelacja - Waluta/Towar
Anthem Inc. Corporate Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-2.74 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-2.74 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-77 000.00 (0.00 %) |
EPS: | $-2.14 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.534 |
Financial Reports:
No articles found.
Anthem Inc. Corporate Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.576 | 2015-07-13 |
Last Dividend | $0.656 | 2018-01-11 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $7.14 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.61 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0.656 | 1.15% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.461 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.590 | 1.500 | -7.67 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.87 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.74 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.114 | 1.500 | 4.92 | 7.38 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 97.26 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.792 | 2.00 | -0.597 | -1.195 | [0 - 30] |
freeCashFlowPerShareTTM | -1.792 | 2.00 | -0.896 | -1.792 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.272 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.189 | 1.000 | -0.221 | 0 | [1 - 100] |
returnOnEquityTTM | -0.590 | 2.50 | -4.93 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.792 | 2.00 | -0.597 | -1.792 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.792 | 2.00 | -0.597 | -1.195 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0207 | 1.500 | -3.20 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.990 |
Anthem Inc. Corporate
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej